title: X-ray crystal structures of Escherichia coli RNA polymerase with switch region binding inhibitors enable rational design of squaramides with an improved fraction unbound to human plasma protein.
abstract: Squaramides constitute a novel class of RNA polymerase inhibitors of which genetic evidence and computational modeling previously have suggested an inhibitory mechanism mediated by binding to the RNA polymerase switch region. An iterative chemistry program increased the fraction unbound to human plasma protein from below minimum detection levels, i.e., <1% to 4-6%, while retaining biochemical potency. Since in vitro antimicrobial activity against an efflux-negative strain of Haemophilus influenzae was 4- to 8-fold higher, the combined improvement was at least 20- to 60-fold. Cocrystal structures of Escherichia coli RNA polymerase with two key squaramides showed displacement of the switch 2, predicted to interfere with the conformational change of the clamp domain and/or with binding of template DNA, a mechanism akin to that of natural product myxopyronin. Furthermore, the structures confirmed the chemical features required for biochemical potency. The terminal isoxazole and benzyl rings bind into distinct relatively narrow, hydrophobic pockets, and both are required for biochemical potency. In contrast, the linker composed of squarate and piperidine accesses different conformations in their respective cocrystal structures with RNA polymerase, reflecting its main role of proper orientation of the aforementioned terminal rings. These observations further explain the tolerance of hydrophilic substitutions in the linker region that was exploited to improve the fraction unbound to human plasma protein while retaining biochemical potency.
authors: †Department of Biochemistry and Molecular Biology, The Center for RNA Molecular Biology, The Pennsylvania State University, University Park, Pennsylvania 16802, United States.
authors: Vadim
authors: V
authors: Molodtsov
authors: Paul R
authors: PR
authors: Fleming
authors: Charles J
authors: CJ
authors: Eyermann
authors: Andrew D
authors: AD
authors: Ferguson
authors: Melinda A
authors: MA
authors: Foulk
authors: David C
authors: DC
authors: McKinney
authors: ⊥Nimbus Therapeutics, Inc., Cambridge, Massachusetts 02141, United States.
authors: Craig E
authors: CE
authors: Masse
authors: Ed T
authors: ET
authors: Buurman
authors: †Department of Biochemistry and Molecular Biology, The Center for RNA Molecular Biology, The Pennsylvania State University, University Park, Pennsylvania 16802, United States.
authors: Katsuhiko S
authors: KS
authors: Murakami
mesh_terms: D001665:Binding Sites; D001798:Blood Proteins / Q000378:metabolism; D060326:Chemistry Techniques, Synthetic; D018360:Crystallography, X-Ray; D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D029968:Escherichia coli Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D006193:Haemophilus influenzae / Q000187:drug effects; D057166:High-Throughput Screening Assays; D006801:Humans; D007783:Lactones / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D008958:Models, Molecular; D011487:Protein Conformation; D013329:Structure-Activity Relationship
chemical_list: D001798:Blood Proteins; D004791:Enzyme Inhibitors; D029968:Escherichia coli Proteins; D007783:Lactones; C540081:rpoB protein, E coli; C040322:myxopyronin A; C040323:myxopyronin B; D012321:DNA-Directed RNA Polymerases; C113275:RNA polymerase alpha subunit